---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059460"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:28:24.857164+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elutia Q1 net sales $6.7M; SimpliDerm up 55%; CanGarooRM FDA decision expected by June 2024

## Summary
- SimpliDerm net sales $3.6M (+55% YoY) driven by accelerated adoption in $1.6B breast reconstruction market.
- CanGarooRM antibiotic-envelope 510(k) submission; positive FDA interactions; clearance anticipated Q2 2024.
- Net loss $18.0M includes $9.6M non-cash warrant revaluation; adjusted EBITDA loss improved to $3.6M.
- Cash balance $12.6M; preparing for CanGarooRM commercial launch in H2 2024.
- Overall net sales $6.7M (+5% YoY); cardiovascular sales declined 56% due to LeMaitre distribution transition.

## SEC filing metadata
- accession: 0001104659-24-059460
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465924059460/0001104659-24-059460-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465924059460/tm2414063d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059460
- JSON: https://secwatch.observer/filing/0001104659-24-059460.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059460.txt

## Key facts
- Earnings Releases
  ELUTIA INC. reported first quarter ended March 31, 2024 results: revenue $6.7 million, net income $18.0 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $6.7 million
  - Net income: $18.0 million
  - Result: reported results
  source text: second half of this year. First Quarter 2024 Financial Results For the three-month period ended March 31, 2024, as compared to the same period of 2023: · Overall net sales were $6.7 million, an increase of 5%. · Net sales of SimpliDerm were $3.6 million, compared to $2.3 million, an increase of 55%, as customer awareness and acceptance accelerated within the $1.6
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708527/000110465924059460/0001104659-24-059460-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.